Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Pfizer
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02201524CT.gov Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Psoriasis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| pf-04965842 (this asset) | Pfizer | P2 | CCC · 53 |
| 1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER | Amgen | P4 | BBB |
| Calcipotriene | Hospital Universitario Dr. Jose E. Gonzalez | P4 | BBB |
| Semaglutide | Hospital Universitario Dr. Jose E. Gonzalez | P4 | BBB |
| cp-690,550 | Pfizer | P3 | BBB |
| Tirzepatide | Eli Lilly and Company | P4 | BBB |
| Secukinumab | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | P4 | BB |
| Adalimumab | Innovaderm Research Inc. | P4 | BB |
| Flosteron | GlaxoSmithKline | P3 | BB |
+16 more in the Psoriasis cohort
Other indications for pf-04965842
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atopic Eczema | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- 1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMERAmgenBBB
- CalcipotrieneHospital Universitario Dr. Jose E. GonzalezBBB
- SemaglutideHospital Universitario Dr. Jose E. GonzalezBBB
- cp-690,550PfizerBBB
- TirzepatideEli Lilly and CompanyBBB
Citation
Floatz Terminal. pf-04965842 in Psoriasis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pf-04965842-psoriasis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →